Yannick Vermeiren

List of Publications by Year
in descending order

48 papers	1,619 citations	361045 20 h-index	344852 36 g-index
61 all docs	61 docs citations	61 times ranked	2338 citing authors

#	Article	IF	Citations
1	The role of serotonin within the microbiota-gut-brain axis in the development of Alzheimerâ€™s disease: A narrative review. Ageing Research Reviews, 2022, 75, 101556.	5.0	44
2	Associating Alzheimerâ€™s disease pathology with its cerebrospinal fluid biomarkers. Brain, 2022, 145, 4056-4064.	3.7	19
3	Plasma 5â€HIAA activity indicative of serotonergic disturbances in cognitively impaired, elderly patients experiencing postoperative delirium. International Journal of Geriatric Psychiatry, 2022, 37, .	1.3	1
4	iPSC-derived cortical neurons to study sporadic Alzheimer disease: A transcriptome comparison with post-mortem brain samples. Toxicology Letters, 2022, 356, 89-99.	0.4	8
5	Distinct amyloid-Î² and tau-associated microglia profiles in Alzheimerâ€™s disease. Acta Neuropathologica, 2021, 141, 681-696.	3.9	167
6	Contribution of rare homozygous and compound heterozygous VPS13C missense mutations to dementia with Lewy bodies and Parkinsonâ€™s disease. Acta Neuropathologica Communications, 2021, 9, 25.	2.4	23
7	Hippocampal Sclerosis in Frontotemporal Dementia: When Vascular Pathology Meets Neurodegeneration. Journal of Neuropathology and Experimental Neurology, 2021, 80, 313-324.	0.9	5
8	Serum Daytime Melatonin Levels Reflect Cerebrospinal Fluid Melatonin Levels in Alzheimerâ€™s Disease but Are Not Correlated with Cognitive Decline. Journal of Alzheimer's Disease, 2021, 83, 693-704.	1.2	1
9	Chronic adolescent stress increases exploratory behavior but does not appear to change the acute stress response in adult male C57BL/6 mice. Neurobiology of Stress, 2021, 15, 100388.	1.9	3
10	5-HT7 receptors in Alzheimer's disease. Neurochemistry International, 2021, 150, 105185.	1.9	12
11	Neurogranin as biomarker in CSF is non-specific to Alzheimer's disease dementia. Neurobiology of Aging, 2021, 108, 99-109.	1.5	13
12	Psychiatric Disorders in Dementia. , 2021, , 317-385.		0
13	Biofluid Markers for Prodromal Parkinson's Disease: Evidence From a Catecholaminergic Perspective. Frontiers in Neurology, 2020, 11, 595.	1.1	7
14	ABCA7 PTC mutation carriers present with Alzheimerâ€™s disease pathology and cerebral amyloid angiopathy. Alzheimer's and Dementia, 2020, 16, e041513.	0.4	0
15	Monoaminergic and Kynurenergic Characterization of Frontotemporal Dementia and Amyotrophic Lateral Sclerosis in Cerebrospinal Fluid and Serum. Neurochemical Research, 2020, 45, 1191-1201.	1.6	12
16	A complete pupillometry toolbox for real-time monitoring of locus coeruleus activity in rodents. Nature Protocols, 2020, 15, 2301-2320.	5.5	46
17	Ageâ€•and diseaseâ€specific changes of the kynurenine pathway in Parkinsonâ€™s and Alzheimerâ€™s disease. Journal of Neurochemistry, 2019, 151, 656-668.	2.1	81
18	Pre-analytical stability of novel cerebrospinal fluid biomarkers. Clinica Chimica Acta, 2019, 497, 204-211.	0.5	9

#	Article	IF	Citations
19	Rapid Reconfiguration of the Functional Connectome after Chemogenetic Locus Coeruleus Activation. Neuron, 2019, 103, 702-718.e5.	3.8	198
20	Sampling issues of cerebrospinal fluid and plasma monoamines: Investigation of the circadian rhythm and rostrocaudal concentration gradient. Neurochemistry International, 2019, 128, 154-162.	1.9	14
21	Monoaminergic Markers Across the Cognitive Spectrum of Lewy Body Disease. Journal of Parkinson's Disease, 2018, 8, 71-84.	1.5	12
22	Cerebrospinal fluid and serum MHPG improve Alzheimer's disease versus dementia with Lewy bodies differential diagnosis. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 172-181.	1.2	16
23	Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to earlyâ€onset Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 99-111.	1.2	9
24	P2â€228: PREâ€ANALYTICAL STABILITY OF NOVEL CEREBROSPINAL FLUID BIOMARKERS FOR DEMENTIA. Alzheimer's and Dementia, 2018, 14, P755.	0.4	0
25	Serotonergic Dysfunction in Amyotrophic Lateral Sclerosis and Parkinson's Disease: Similar Mechanisms, Dissimilar Outcomes. Frontiers in Neuroscience, 2018, 12, 185.	1.4	32
26	The Behavioral and Psychological Symptoms of Dementia in Down Syndrome (BPSD-DS) Scale: Comprehensive Assessment of Psychopathology in Down Syndrome. Journal of Alzheimer's Disease, 2018, 63, 797-819.	1.2	38
27	Targeting the norepinephrinergic system in Parkinson's disease and related disorders: The locus coeruleus story. Neurochemistry International, 2017, 102, 22-32.	1.9	95
28	Aging rather than aneuploidy affects monoamine neurotransmitters in brain regions of Down syndrome mouse models. Neurobiology of Disease, 2017, 105, 235-244.	2.1	14
29	[P4â€“405]: MONOAMINERGIC CORRELATES OF DISINHIBITED BEHAVIOURS IN THE NOVEL TAU58/4 TRANSGENIC MOUSE MODEL FOR TAUOPATHY. Alzheimer's and Dementia, 2017, 13, P1486.	0.4	0
30	[P4â€“473]: BIOLOGICAL FLUID MONOAMINE LEVELS TO EXPLORE THE NEUROCHEMICAL CONTINUUM BETWEEN FRONTOTEMPORAL DEMENTIA AND AMYOTROPHIC LATERAL SCLEROSIS. Alzheimer's and Dementia, 2017, 13, P1514.	0.4	0
31	Neuropsychiatric Disturbances in Alzheimer's Disease: What Have We Learned from Neuropathological Studies?. Current Alzheimer Research, 2016, 13, 1145-1164.	0.7	50
32	Neutrophil Gelatinase-Associated Lipocalin and its Receptors in Alzheimerâ€™s Disease (AD) Brain Regions: Differential Findings in AD with and without Depression. Journal of Alzheimer's Disease, 2016, 55, 763-776.	1.2	39
33	Brain Serotonergic and Noradrenergic Deficiencies in Behavioral Variant Frontotemporal Dementia Compared to Early-Onset Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 53, 1079-1096.	1.2	33
34	Serum NGAL is Associated with Distinct Plasma Amyloid-Î² Peptides According to the Clinical Diagnosis of Dementia in Down Syndrome. Journal of Alzheimer's Disease, 2015, 45, 733-743.	1.2	17
35	The monoaminergic footprint of depression and psychosis in dementia with Lewy bodies compared to Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2015, 7, 7.	3.0	47
36	Behavioural and psychological symptoms ofÂdementia in Down syndrome: Early indicators ofÂclinical Alzheimer's disease?. Cortex, 2015, 73, 36-61.	1.1	201

#	Article	IF	Citations
37	Psychiatric Disorders in Dementia. , 2014, , 271-324.		1
38	Novel and sensitive reversed-phase high-pressure liquid chromatography method with electrochemical detection for the simultaneous and fast determination of eight biogenic amines and metabolites in human brain tissue. Journal of Chromatography A, 2014, 1353, 28-39.	1.8	36
39	Monoaminergic neurotransmitter alterations in postmortem brain regions of depressed and aggressive patients with Alzheimer's disease. Neurobiology of Aging, 2014, 35, 2691-2700.	1.5	70
40	Brain Region-Specific Monoaminergic Correlates of Neuropsychiatric Symptoms in Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 41, 819-833.	1.2	53
41	Serum MHPG Strongly Predicts Conversion to Alzheimer's Disease in Behaviorally Characterized Subjects with Down Syndrome. Journal of Alzheimer's Disease, 2014, 43, 871-891.	1.2	32
42	P1-112: MONOAMINERGIC BRAIN TOPOCHEMISTRY IN ALZHEIMER'S DISEASE VERSUS HEALTHY ELDERLY. , 2014, 10, P342-P342.		0
43	P2-148: MONOAMINERGIC NEUROTRANSMITTER LEVELS IN POST-MORTEM BRAIN REGIONS OF PATIENTS WITH LEWY BODY AND ALZHEIMER'S DEMENTIA: ASSOCIATION WITH DEPRESSION AND PSYCHOSIS. , 2014, 10, P526-P526.		0
44	Behavioral symptoms in mild cognitive impairment as compared with Alzheimer's disease and healthy older adults. International Journal of Geriatric Psychiatry, 2013, 28, 265-275.	1.3	50
45	Behavioral correlates of cerebrospinal fluid amino acid and biogenic amine neurotransmitter alterations in dementia. Alzheimer's and Dementia, 2013, 9, 488-498.	0.4	37
46	Prevalence and associated behavioral symptoms of depression in mild cognitive impairment and dementia due to Alzheimer's disease. International Journal of Geriatric Psychiatry, 2013, 28, 947-958.	1.3	58
47	Serum Glutamine Synthetase Has No Value as a Diagnostic Biomarker for Alzheimerâ€™s Disease. Neurochemical Research, 2011, 36, 1858-1862.	1.6	3
48	Rapid Reconfiguration of the Functional Connectome after Chemogenetic Locus Coeruleus Activation. SSRN Electronic Journal, 0, , .	0.4	1